Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Do the Challenges Outweigh the Potential of Using ChatGPT in CDI?

Chat GPT in CDI (Clinical Documentation Integrity) is real. In the rapidly evolving realm of artificial intelligence (AI), the chatter has reached a fever pitch around the potential uses of ChatGPT, OpenAI’s conversational AI model. Since its unveiling in November 2022, advocates have championed the technology’s potential in sectors as varied as healthcare,…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Iodine Software on MarketScale.

Share
Do the Challenges Outweigh the Potential of Using ChatGPT in CDI?

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Chat GPT in CDI (Clinical Documentation Integrity) is real. In the rapidly evolving realm of artificial intelligence (AI), the chatter has reached a fever pitch around the potential uses of ChatGPT, OpenAI’s conversational AI model. Since its unveiling in November 2022, advocates have championed the technology’s potential in sectors as varied as healthcare, marketing, law, and education. The Clinical Documentation Integrity (CDI) space is in the crosshairs of this discussion, especially as AI continues to reshape healthcare delivery. There are already concerns about potential malpractice risks associated with the use of AI. Still, the question remains: can ChatGPT in CDI solve all its related issues and challenges?

The Iodine Intelligence podcast, hosted by Iodine Software’s Marketing Manager, Lauren Hickey, grapples with this timely question. Hickey’s guest, Fran Jurcak, Chief Clinical Officer at Iodine Software, joined the conversation to dissect the implications of ChatGPT in CDI.

Hickey and Jurcak discuss the following:

  • The capabilities and limitations of ChatGPT and its underlying Natural Language Processing (NLP) technology in the context of CDI
  • The potential issues with the biases inherent in AI technologies, including ChatGPT
  • The future possibilities for CDI through a blend of AI technologies and whether ChatGPT could play a role in that solution

Fran Jurcak, a seasoned healthcare leader and the Chief Clinical Officer at Iodine Software, brings a wealth of knowledge and experience to this conversation. Known for her clinical strategy expertise, Jurcak has been instrumental in exploring and applying AI’s potential within the CDI landscape, leveraging her rich background in healthcare, nursing, and technology to chart a forward-thinking path for Iodine Software.

ChatGPT’s potential in CDI is a complex issue, as the conversation reveals. While the technology’s ability to generate original content based on a user’s request shows promise, its limitations—specifically, its inability to interpret information contextually and identify missing data—pose significant challenges, including whether or not physicians will meticulously check the work for accuracy. Moreover, the AI’s existing biases, fueled by the online textual data used for training, could present serious ethical implications when applied to medical documentation. According to Jurcak, while ChatGPT alone may not be the magic bullet for CDI, its integration with other AI technologies could open new avenues for innovation in the future.

Iodine Software

Part of this channel

Iodine Software

AI-powered clinical documentation that helps hospitals capture accurate revenue.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512